Curis Inc

Curis Inc has a market capitalization of $23.99 million and a price-to-book ratio of 4.39, indicating that the market is valuing the company at a premium to its book value. The company's liquidity position is weak, as evidenced by a current ratio of 0.49, which suggests that the company's current liabilities exceed its current assets. The company has no long-term debt, but its operating cash flow is negative at -$27.20 million, and its free cash flow is also negative at -$7.38 million, indicating that the company is not generating sufficient cash from operations to fund its activities. In terms of profitability, Curis Inc is currently unprofitable, with a net loss of $7.58 million and an operating loss of $5.71 million. The company's return on equity is -138.81%, and its return on assets is -37.97%, both of which are significantly below the industry median for biotechnology companies. The company's gross profit margin is 99.52%, which is high, but this is offset by high operating expenses that result in a negative operating margin. Curis Inc's revenue is concentrated in a single business segment, as the company does not disclose multiple segments in its financial reporting. The company's geographic exposure is primarily in the United States, as it is a U.S.-based biotechnology company with no significant international operations disclosed in its financial statements. The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections for the current or next fiscal year. However, the company's negative operating and net income suggest that it is not currently growing profitably. The company's revenue for the most recent period was $9.44 million, and there is no indication of a significant increase in revenue in the near term. The company's risk profile is characterized by low liquidity and low dilution risk. The company has no immediate filing-based liquidity or dilution flags, and its dilution potential is low, as there is no indication of a significant increase in shares outstanding in the near term. The company's financial position is supported by $5.06 million in cash and equivalents, but this is not sufficient to cover its operating cash flow deficit. Recent events related to Curis Inc include the publication of its latest financial results, which show a continuation of its unprofitable operations. The company has not disclosed any significant new product launches or strategic partnerships in its most recent filings. The company's stock is currently trading at $0.60 per share, and analyst price targets range from $5.00 to $20.00, with a mean price target of $14.00 and a median price target of $17.00. The mean recommendation from analysts is 2.00, which is a "Buy" rating.